We can't find the internet
Attempting to reconnect
Something went wrong!
Hang in there while we get back on track
| Form | Report Date | Filing Date | Description |
|---|---|---|---|
| 6-K | 2026-10-14 | 2026-10-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-10-13 | 2026-10-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-10-13 | 2026-10-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-10-08 | 2026-10-08 | WENDY BECKER CBE - NEW DIRECTORSHIP |
| 6-K | 2026-10-06 | 2026-10-06 | ADMISSION TO TRADING |
| 6-K | 2026-10-01 | 2026-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-09-24 | 2026-09-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-22 | 2026-09-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-15 | 2026-09-15 | 6-K |
| 6-K | 2026-09-15 | 2026-09-15 | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA |
| 6-K | 2026-09-14 | 2026-09-14 | RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA |
| 6-K | 2026-09-14 | 2026-09-14 | JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC |
| 6-K | 2026-09-11 | 2026-09-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-10 | 2026-09-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-10 | 2026-09-10 | JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE |
| 6-K | 2026-09-09 | 2026-09-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-09 | 2026-09-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-09-08 | 2026-09-08 | 6-K |
| 6-K | 2026-09-01 | 2026-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-09-01 | 2026-09-01 | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III |
| 6-K | 2026-08-26 | 2026-08-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-08-24 | 2026-08-24 | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER |
| 6-K | 2026-08-24 | 2026-08-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-08-24 | 2026-08-24 | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN |
| 6-K | 2026-08-18 | 2026-08-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-08-13 | 2026-08-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-08-11 | 2026-08-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-08-03 | 2026-08-03 | TOTAL VOTING RIGHTS |
| 6-K | 2026-07-30 | 2026-07-30 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-07-28 | 2026-07-28 | 2ND QUARTER RESULTS |
| 6-K | 2026-07-28 | 2026-07-28 | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE |
| 6-K | 2026-07-28 | 2026-07-28 | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ |
| 6-K | 2026-07-24 | 2026-07-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-07-24 | 2026-07-24 | ADMISSION TO TRADING |
| 6-K | 2026-07-22 | 2026-07-22 | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS |
| 6-K | 2026-07-20 | 2026-07-20 | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE |
| 6-K | 2026-07-17 | 2026-07-17 | CAMLIPIXANT PHASE III RESULTS UPDATE |
| 6-K | 2026-07-17 | 2026-07-17 | AUDIT TENDER CONCLUSION |
| 6-K | 2026-07-16 | 2026-07-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-07-15 | 2026-07-15 | GSK COMPLETES ACQUISITION OF NUVALENT, INC |
| 6-K | 2026-07-14 | 2026-07-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-07-13 | 2026-07-13 | POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER |
| 6-K | 2026-07-13 | 2026-07-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-07-10 | 2026-07-10 | HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ |
| 6-K | 2026-07-09 | 2026-07-09 | DIRECTORATE CHANGE |
| 6-K | 2026-07-09 | 2026-07-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-07-01 | 2026-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-06-29 | 2026-06-29 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-06-29 | 2026-06-29 | HOLDING(S) IN COMPANY |
| 6-K | 2026-06-26 | 2026-06-26 | HOLDING(S) IN COMPANY |
| 6-K | 2026-06-24 | 2026-06-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-06-24 | 2026-06-24 | GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT |
| 6-K | 2026-06-23 | 2026-06-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-06-22 | 2026-06-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-06-17 | 2026-06-17 | CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA |
| 6-K | 2026-06-15 | 2026-06-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-06-12 | 2026-06-12 | MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS |
| 6-K | 2026-06-11 | 2026-06-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-06-10 | 2026-06-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-06-09 | 2026-06-09 | DR HAL BARRON - NEW DIRECTORSHIP |
| 6-K | 2026-06-09 | 2026-06-09 | GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. |
| 6-K | 2026-06-08 | 2026-06-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-06-01 | 2026-06-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-06-01 | 2026-06-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-05-28 | 2026-05-28 | POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN |
| 6-K | 2026-05-27 | 2026-05-27 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-26 | 2026-05-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-05-26 | 2026-05-26 | ADMISSION TO TRADING |
| 6-K | 2026-05-22 | 2026-05-22 | Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026 |
| 6-K | 2026-05-20 | 2026-05-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-20 | 2026-05-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-19 | 2026-05-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-18 | 2026-05-18 | JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR |
| 6-K | 2026-05-18 | 2026-05-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-05-14 | 2026-05-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-11 | 2026-05-11 | COLLABORATION WITH CTTQ FOR BEPIROVIRSEN |
| 6-K | 2026-05-11 | 2026-05-11 | GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME |
| 6-K | 2026-05-11 | 2026-05-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-06 | 2026-05-06 | RESULT OF AGM |
| 6-K | 2026-05-05 | 2026-05-05 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-05-01 | 2026-05-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-05-01 | 2026-05-01 | HOLDING(S) IN COMPANY |
| 6-K | 2026-04-29 | 2026-04-29 | 1ST QUARTER RESULTS |
| 6-K | 2026-04-29 | 2026-04-29 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-28 | 2026-04-28 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-28 | 2026-04-28 | BEPIROVIRSEN PRIORITY REVIEW US FILING ACCEPTANCE |
| 6-K | 2026-04-27 | 2026-04-27 | EFIMOSFERMIN GRANTED US/EU REGULATORY DESIGNATIONS |
| 6-K | 2026-04-27 | 2026-04-27 | TESARO UPDATE ON ANAPTYSBIO INC. LITIGATION |
| 6-K | 2026-04-24 | 2026-04-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-23 | 2026-04-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-22 | 2026-04-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-21 | 2026-04-21 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-20 | 2026-04-20 | BLENREP APPROVED IN CHINA FOR 2L+ MULTIPLE MYELOMA |
| 6-K | 2026-04-20 | 2026-04-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-20 | 2026-04-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-17 | 2026-04-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-16 | 2026-04-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-16 | 2026-04-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-15 | 2026-04-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-15 | 2026-04-15 | GSK COMPLETES ACQUISITION OF 35PHARMA INC. |
| 6-K | 2026-04-14 | 2026-04-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-14 | 2026-04-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-13 | 2026-04-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-13 | 2026-04-13 | GSK PRESENTS POSITIVE DATA FOR BEHOLD 1 B7 H4 ADC |
| 6-K | 2026-04-13 | 2026-04-13 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-10 | 2026-04-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-10 | 2026-04-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-09 | 2026-04-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-09 | 2026-04-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-08 | 2026-04-08 | EXDENSUR APPROVED FOR CRSWNP IN CHINA |
| 6-K | 2026-04-08 | 2026-04-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-07 | 2026-04-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-02 | 2026-04-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-01 | 2026-04-01 | VIIV COMPLETES CHANGES TO MINORITY SHAREHOLDING |
| 6-K | 2026-04-01 | 2026-04-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-04-01 | 2026-04-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-04-01 | 2026-04-01 | TOTAL VOTING RIGHTS |
| 6-K | 2026-03-31 | 2026-03-31 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-30 | 2026-03-30 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-30 | 2026-03-30 | BEPIROVIRSEN ACCEPTED FOR REVIEW IN CHINA |
| 6-K | 2026-03-30 | 2026-03-30 | EXDENSUR APPROVED FOR SEVERE ASTHMA IN CHINA |
| 6-K | 2026-03-27 | 2026-03-27 | BEPIROVIRSEN ACCEPTED FOR REVIEW BY THE EMA |
| 6-K | 2026-03-27 | 2026-03-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-26 | 2026-03-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-25 | 2026-03-25 | NOTICE OF AGM |
| 6-K | 2026-03-25 | 2026-03-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-25 | 2026-03-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-24 | 2026-03-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-23 | 2026-03-23 | ADMISSION TO TRADING |
| 6-K | 2026-03-23 | 2026-03-23 | GSK LUNG CANCER ADC GETS JAPAN ORPHAN DRUG STATUS |
| 6-K | 2026-03-23 | 2026-03-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-23 | 2026-03-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-20 | 2026-03-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-19 | 2026-03-19 | LYNAVOY (LINERIXIBAT) APPROVED BY US FDA |
| 6-K | 2026-03-19 | 2026-03-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-18 | 2026-03-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-18 | 2026-03-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-17 | 2026-03-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-17 | 2026-03-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-16 | 2026-03-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-13 | 2026-03-13 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-13 | 2026-03-13 | US FDA APPROVES AREXVY FOR ADULTS 18-49 AIR |
| 6-K | 2026-03-12 | 2026-03-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-12 | 2026-03-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-11 | 2026-03-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-10 | 2026-03-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-09 | 2026-03-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-09 | 2026-03-09 | GSK AND ALFASIGMA AGREE GLOBAL LINERIXIBAT RIGHTS |
| 6-K | 2026-03-09 | 2026-03-09 | BOARD COMMITTEE CHANGE |
| 6-K | 2026-03-06 | 2026-03-06 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-06 | 2026-03-06 | FILING OF GSK PLC 2025 ANNUAL REPORT ON FORM 20-F |
| 20-F | 2025-12-31 | 2026-03-06 | 20-F |
| 6-K | 2026-03-05 | 2026-03-05 | GSK PUBLISHES ANNUAL REPORT 2025 |
| 6-K | 2026-03-05 | 2026-03-05 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-04 | 2026-03-04 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-03-04 | 2026-03-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-03 | 2026-03-03 | GSK COMPLETES ACQUISITION OF RAPT THERAPEUTICS |
| 6-K | 2026-03-03 | 2026-03-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-03-02 | 2026-03-02 | TOTAL VOTING RIGHTS |
| 6-K | 2026-03-02 | 2026-03-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-27 | 2026-02-27 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-27 | 2026-02-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-26 | 2026-02-26 | BEPIROVIRSEN ACCEPTED FOR JAPAN REGULATORY REVIEW |
| 6-K | 2026-02-26 | 2026-02-26 | LINERIXIBAT ACCEPTED FOR PRIORITY REVIEW IN CHINA |
| 6-K | 2026-02-26 | 2026-02-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-25 | 2026-02-25 | GSK ENTERS AGREEMENT TO ACQUIRE 35PHARMA |
| 6-K | 2026-02-25 | 2026-02-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-25 | 2026-02-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-25 | 2026-02-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-24 | 2026-02-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-24 | 2026-02-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-23 | 2026-02-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-20 | 2026-02-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-20 | 2026-02-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-19 | 2026-02-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-19 | 2026-02-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-18 | 2026-02-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2026-02-17 | 2026-02-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-17 | 2026-02-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-17 | 2026-02-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-17 | 2026-02-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-17 | 2026-02-17 | EXDENSUR APPROVED BY THE EUROPEAN COMMISSION |
| 6-K | 2026-02-17 | 2026-02-17 | GSK - FOURTH TRANCHE OF SHARE BUYBACK PROGRAMME |
| 6-K | 2026-02-17 | 2026-02-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-11 | 2026-02-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-11 | 2026-02-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-11 | 2026-02-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-11 | 2026-02-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-10 | 2026-02-10 | CHINA CDE ACCEPTS AREXVY ADULTS 60+ APPLICATION |
| 6-K | 2026-02-09 | 2026-02-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-06 | 2026-02-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-06 | 2026-02-06 | NUCALA COPD APPROVED BY THE EUROPEAN COMMISSION |
| 6-K | 2026-02-05 | 2026-02-05 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-02-04 | 2026-02-04 | FINAL RESULTS |
| 6-K | 2026-02-02 | 2026-02-02 | TOTAL VOTING RIGHTS |
| 6-K | 2026-01-26 | 2026-01-26 | EUROPEAN COMMISSION APPROVES AREXVY FOR ADULTS 18+ |
| 6-K | 2026-01-20 | 2026-01-20 | AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING |
| 6-K | 2026-01-20 | 2026-01-20 | GSK TO ACQUIRE RAPT THERAPEUTICS |
| 6-K | 2026-01-16 | 2026-01-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-01-15 | 2026-01-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-01-13 | 2026-01-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2026-01-07 | 2026-01-07 | POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN |
| 6-K | 2026-01-07 | 2026-01-07 | EC APPROVAL OF SHINGRIX PFS |
| 6-K | 2026-01-06 | 2026-01-06 | EXDENSUR APPROVED IN JAPAN |
| 6-K | 2026-01-05 | 2026-01-05 | NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA |
| 6-K | 2026-01-05 | 2026-01-05 | TOTAL VOTING RIGHTS |
| 6-K | 2026-01-05 | 2026-01-05 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-12-23 | 2025-12-23 | GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US |
| 6-K | 2025-12-22 | 2025-12-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-22 | 2025-12-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-12-19 | 2025-12-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-18 | 2025-12-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-17 | 2025-12-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-17 | 2025-12-17 | EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA |
| 6-K | 2025-12-16 | 2025-12-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-16 | 2025-12-16 | EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL |
| 6-K | 2025-12-15 | 2025-12-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-12 | 2025-12-12 | POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ |
| 6-K | 2025-12-12 | 2025-12-12 | DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION |
| 6-K | 2025-12-12 | 2025-12-12 | NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD |
| 6-K | 2025-12-12 | 2025-12-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-11 | 2025-12-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-12-11 | 2025-12-11 | BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION |
| 6-K | 2025-12-11 | 2025-12-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-11 | 2025-12-11 | BLOCK LISTING APPLICATION |
| 6-K | 2025-12-10 | 2025-12-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-10 | 2025-12-10 | GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC |
| 6-K | 2025-12-09 | 2025-12-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-12-09 | 2025-12-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-08 | 2025-12-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-05 | 2025-12-05 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-04 | 2025-12-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-03 | 2025-12-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-02 | 2025-12-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-12-01 | 2025-12-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-12-01 | 2025-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-12-01 | 2025-12-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-28 | 2025-11-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-28 | 2025-11-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-26 | 2025-11-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-25 | 2025-11-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-24 | 2025-11-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-21 | 2025-11-21 | INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC |
| 6-K | 2025-11-21 | 2025-11-21 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-20 | 2025-11-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-19 | 2025-11-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-19 | 2025-11-19 | TRANSFER OF TREASURY SHARES |
| 6-K | 2025-11-18 | 2025-11-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-11-18 | 2025-11-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-17 | 2025-11-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-14 | 2025-11-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-13 | 2025-11-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-11-13 | 2025-11-13 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-12 | 2025-11-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-12 | 2025-11-12 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2025-11-12 | 2025-11-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-10 | 2025-11-10 | GSK PUBLISHES PROVISIONAL DIVIDEND DATES |
| 6-K | 2025-11-10 | 2025-11-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-07 | 2025-11-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-06 | 2025-11-06 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-05 | 2025-11-05 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-04 | 2025-11-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-03 | 2025-11-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-11-03 | 2025-11-03 | TOTAL VOTING RIGHTS |
| 6-K | 2025-10-31 | 2025-10-31 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-30 | 2025-10-30 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-10-30 | 2025-10-30 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-29 | 2025-10-29 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-29 | 2025-10-29 | 3RD QUARTER RESULTS |
| 6-K | 2025-10-28 | 2025-10-28 | GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU |
| 6-K | 2025-10-28 | 2025-10-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-27 | 2025-10-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-24 | 2025-10-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-24 | 2025-10-24 | BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA |
| 6-K | 2025-10-23 | 2025-10-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-22 | 2025-10-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-22 | 2025-10-22 | POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI |
| 6-K | 2025-10-22 | 2025-10-22 | LATOZINEMAB DATA READ OUT |
| 6-K | 2025-10-21 | 2025-10-21 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-21 | 2025-10-21 | POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS |
| 6-K | 2025-10-21 | 2025-10-21 | GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR |
| 6-K | 2025-10-20 | 2025-10-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-17 | 2025-10-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-16 | 2025-10-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-16 | 2025-10-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-10-15 | 2025-10-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-10-15 | 2025-10-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-14 | 2025-10-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-14 | 2025-10-14 | GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA |
| 6-K | 2025-10-14 | 2025-10-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-14 | 2025-10-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-10-10 | 2025-10-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-10-10 | 2025-10-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-09 | 2025-10-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-08 | 2025-10-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-07 | 2025-10-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-06 | 2025-10-06 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-03 | 2025-10-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-02 | 2025-10-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-01 | 2025-10-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-10-01 | 2025-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-09-30 | 2025-09-30 | GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME |
| 6-K | 2025-09-29 | 2025-09-29 | GSK APPOINTS CEO DESIGNATE |
| 6-K | 2025-09-22 | 2025-09-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-09-19 | 2025-09-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-18 | 2025-09-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-17 | 2025-09-17 | GSK US INVESTMENT ANNOUNCEMENT |
| 6-K | 2025-09-17 | 2025-09-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-16 | 2025-09-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-15 | 2025-09-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-12 | 2025-09-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-11 | 2025-09-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-10 | 2025-09-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-09-10 | 2025-09-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-09 | 2025-09-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-08 | 2025-09-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-05 | 2025-09-05 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-04 | 2025-09-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-04 | 2025-09-04 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-09-03 | 2025-09-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-02 | 2025-09-02 | TOTAL VOTING RIGHTS |
| 6-K | 2025-09-02 | 2025-09-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-09-02 | 2025-09-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-29 | 2025-08-29 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-28 | 2025-08-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-27 | 2025-08-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-26 | 2025-08-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-22 | 2025-08-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-21 | 2025-08-21 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-21 | 2025-08-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-08-20 | 2025-08-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-19 | 2025-08-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-08-19 | 2025-08-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-18 | 2025-08-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-15 | 2025-08-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-14 | 2025-08-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-13 | 2025-08-13 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-12 | 2025-08-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-08-12 | 2025-08-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-11 | 2025-08-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-11 | 2025-08-11 | FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN |
| 6-K | 2025-08-08 | 2025-08-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-08 | 2025-08-08 | CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT |
| 6-K | 2025-08-07 | 2025-08-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-06 | 2025-08-06 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-05 | 2025-08-05 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-04 | 2025-08-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-01 | 2025-08-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-08-01 | 2025-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-07-31 | 2025-07-31 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-30 | 2025-07-30 | 2ND QUARTER RESULTS |
| 6-K | 2025-07-30 | 2025-07-30 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-29 | 2025-07-29 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-28 | 2025-07-28 | GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS |
| 6-K | 2025-07-28 | 2025-07-28 | PRIMARY DOCUMENT |
| 6-K | 2025-07-25 | 2025-07-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-24 | 2025-07-24 | BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA |
| 6-K | 2025-07-24 | 2025-07-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-23 | 2025-07-23 | US FDA REVIEW EXTENDED FOR BLENREP |
| 6-K | 2025-07-23 | 2025-07-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-22 | 2025-07-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-21 | 2025-07-21 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-18 | 2025-07-18 | BLENREP US ODAC OUTCOME |
| 6-K | 2025-07-18 | 2025-07-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-07-18 | 2025-07-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-17 | 2025-07-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-17 | 2025-07-17 | GSKS SHINGRIX FULLY LIQUID FDA APPROVAL |
| 6-K | 2025-07-16 | 2025-07-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-15 | 2025-07-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-15 | 2025-07-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-07-14 | 2025-07-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-14 | 2025-07-14 | GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA |
| 6-K | 2025-07-14 | 2025-07-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-07-11 | 2025-07-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-10 | 2025-07-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-09 | 2025-07-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-08 | 2025-07-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-07 | 2025-07-07 | GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD |
| 6-K | 2025-07-07 | 2025-07-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-07 | 2025-07-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-03 | 2025-07-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-02 | 2025-07-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-01 | 2025-07-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-07-01 | 2025-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-06-30 | 2025-06-30 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-27 | 2025-06-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-26 | 2025-06-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-25 | 2025-06-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-24 | 2025-06-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-24 | 2025-06-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-06-24 | 2025-06-24 | DIRECTOR DECLARATION |
| 6-K | 2025-06-23 | 2025-06-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-06-23 | 2025-06-23 | LINERIXIBAT FILE ACCEPTED BY EMA |
| 6-K | 2025-06-23 | 2025-06-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-20 | 2025-06-20 | AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK |
| 6-K | 2025-06-20 | 2025-06-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-20 | 2025-06-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-18 | 2025-06-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-17 | 2025-06-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-16 | 2025-06-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-13 | 2025-06-13 | GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA |
| 6-K | 2025-06-13 | 2025-06-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-06-13 | 2025-06-13 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-12 | 2025-06-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-12 | 2025-06-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-06-11 | 2025-06-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-06-11 | 2025-06-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-10 | 2025-06-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-09 | 2025-06-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-06 | 2025-06-06 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-05 | 2025-06-05 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-04 | 2025-06-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-04 | 2025-06-04 | GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME |
| 6-K | 2025-06-03 | 2025-06-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-02 | 2025-06-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-06-02 | 2025-06-02 | LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA |
| 6-K | 2025-06-02 | 2025-06-02 | TOTAL VOTING RIGHTS |
| 6-K | 2025-06-02 | 2025-06-02 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-05-30 | 2025-05-30 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-29 | 2025-05-29 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-28 | 2025-05-28 | GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY |
| 6-K | 2025-05-28 | 2025-05-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-27 | 2025-05-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-23 | 2025-05-23 | POSITIVE CHMP OPINION ON BLENREP IN EU |
| 6-K | 2025-05-23 | 2025-05-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-23 | 2025-05-23 | FDA APPROVES NUCALA COPD INDICATION |
| 6-K | 2025-05-22 | 2025-05-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-21 | 2025-05-21 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-20 | 2025-05-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-20 | 2025-05-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-05-19 | 2025-05-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-19 | 2025-05-19 | BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN |
| 6-K | 2025-05-16 | 2025-05-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-15 | 2025-05-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-14 | 2025-05-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-14 | 2025-05-14 | GSK TO ACQUIRE EFIMOSFERMIN |
| 6-K | 2025-05-13 | 2025-05-13 | UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME |
| 6-K | 2025-05-13 | 2025-05-13 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-13 | 2025-05-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-05-12 | 2025-05-12 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2025-05-12 | 2025-05-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-09 | 2025-05-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-08 | 2025-05-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-08 | 2025-05-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-05-08 | 2025-05-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-05-08 | 2025-05-08 | LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL |
| 6-K | 2025-05-07 | 2025-05-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-07 | 2025-05-07 | RESULT OF AGM |
| 6-K | 2025-05-06 | 2025-05-06 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-02 | 2025-05-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-01 | 2025-05-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-05-01 | 2025-05-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-05-01 | 2025-05-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-05-01 | 2025-05-01 | NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM |
| 6-K | 2025-04-30 | 2025-04-30 | 1ST QUARTER RESULTS |
| 6-K | 2025-04-30 | 2025-04-30 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-29 | 2025-04-29 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-28 | 2025-04-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-25 | 2025-04-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-24 | 2025-04-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-23 | 2025-04-23 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-22 | 2025-04-22 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-17 | 2025-04-17 | BLENREP LICENSED BY UK MHRA |
| 6-K | 2025-04-17 | 2025-04-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-04-17 | 2025-04-17 | AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS |
| 6-K | 2025-04-17 | 2025-04-17 | GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US |
| 6-K | 2025-04-17 | 2025-04-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-16 | 2025-04-16 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-15 | 2025-04-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-04-15 | 2025-04-15 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-14 | 2025-04-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-14 | 2025-04-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-04-11 | 2025-04-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-04-11 | 2025-04-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-10 | 2025-04-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-09 | 2025-04-09 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-08 | 2025-04-08 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-07 | 2025-04-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-04 | 2025-04-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-03 | 2025-04-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-02 | 2025-04-02 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-01 | 2025-04-01 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-04-01 | 2025-04-01 | TOTAL VOTING RIGHTS |
| 6-K | 2025-03-31 | 2025-03-31 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-28 | 2025-03-28 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-03-28 | 2025-03-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-27 | 2025-03-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-26 | 2025-03-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-25 | 2025-03-25 | GSK UUTI TREATMENT APPROVED BY US FDA |
| 6-K | 2025-03-25 | 2025-03-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-24 | 2025-03-24 | EMA FILING ACCEPTANCE FOR NUCALA COPD |
| 6-K | 2025-03-24 | 2025-03-24 | NOTICE OF AGM |
| 6-K | 2025-03-24 | 2025-03-24 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-21 | 2025-03-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-03-21 | 2025-03-21 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-20 | 2025-03-20 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-19 | 2025-03-19 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-18 | 2025-03-18 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-17 | 2025-03-17 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-14 | 2025-03-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-03-14 | 2025-03-14 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-13 | 2025-03-13 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-13 | 2025-03-13 | 6-K |
| 6-K | 2025-03-12 | 2025-03-12 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-11 | 2025-03-11 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-10 | 2025-03-10 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-07 | 2025-03-07 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-06 | 2025-03-06 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-05 | 2025-03-05 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-04 | 2025-03-04 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-03 | 2025-03-03 | ANCHOR RESULTS PRESENTED AT 2025 AAAAI |
| 6-K | 2025-03-03 | 2025-03-03 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-03-03 | 2025-03-03 | GSK PLC 2024 ANNUAL REPORT ON FORM 20-F |
| 20-F | 2024-12-31 | 2025-03-03 | 20-F |
| 6-K | 2025-03-03 | 2025-03-03 | TOTAL VOTING RIGHTS |
| 6-K | 2025-03-03 | 2025-03-03 | US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS |
| 6-K | 2025-02-28 | 2025-02-28 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-02-27 | 2025-02-27 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-02-27 | 2025-02-27 | GSK PUBLISHES ANNUAL REPORT 2024 |
| 6-K | 2025-02-26 | 2025-02-26 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-02-26 | 2025-02-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-25 | 2025-02-25 | TRANSACTION IN OWN SHARES |
| 6-K | 2025-02-24 | 2025-02-24 | GSK COMPLETES ACQUISITION OF IDRX, INC. |
| 6-K | 2025-02-24 | 2025-02-24 | GSK PLC COMMENCES SHARE BUYBACK PROGRAMME |
| 6-K | 2025-02-21 | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-21 | 2025-02-21 | DIRECTORATE CHANGE |
| 6-K | 2025-02-21 | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-21 | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-21 | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-21 | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-21 | 2025-02-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-20 | 2025-02-20 | NUCALA COPD SUBMISSION ACCEPTED IN CHINA |
| 6-K | 2025-02-18 | 2025-02-18 | GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA |
| 6-K | 2025-02-13 | 2025-02-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-11 | 2025-02-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-02-05 | 2025-02-05 | FINAL RESULTS |
| 6-K | 2025-02-03 | 2025-02-03 | TOTAL VOTING RIGHTS |
| 6-K | 2025-01-28 | 2025-01-28 | EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB |
| 6-K | 2025-01-28 | 2025-01-28 | DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN |
| 6-K | 2025-01-27 | 2025-01-27 | EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION |
| 6-K | 2025-01-21 | 2025-01-21 | JEMPERLI EXPANDED APPROVAL IN THE EU |
| 6-K | 2025-01-16 | 2025-01-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-01-15 | 2025-01-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-01-14 | 2025-01-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2025-01-13 | 2025-01-13 | GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. |
| 6-K | 2025-01-13 | 2025-01-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-01-10 | 2025-01-10 | SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW |
| 6-K | 2024-01-07 | 2025-01-07 | GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION |
| 6-K | 2025-01-03 | 2025-01-03 | GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP |
| 6-K | 2025-01-02 | 2025-01-02 | TOTAL VOTING RIGHTS |
| 6-K | 2024-12-23 | 2024-12-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-12-20 | 2024-12-20 | BLOCK LISTING APPLICATION |
| 6-K | 2024-12-20 | 2024-12-20 | HEADLINE RESULTS FROM PHASE III FIRST TRIAL |
| 6-K | 2024-12-16 | 2024-12-16 | JEMPERLI RECEIVES POSITIVE CHMP OPINION |
| 6-K | 2024-12-16 | 2024-12-16 | JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION |
| 6-K | 2024-12-16 | 2024-12-16 | EMA GRANTS PRIME DESIGNATION FOR GSK 227 |
| 6-K | 2024-12-12 | 2024-12-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-12-09 | 2024-12-09 | OVERALL SURVIVAL DATA PRESENTED FOR BLENREP |
| 6-K | 2024-12-09 | 2024-12-09 | BLENREP COMBINATION CHINA FILING ACCEPTANCE |
| 6-K | 2024-12-09 | 2024-12-09 | NUCALA COPD SUBMISSION ACCEPTED BY US FDA |
| 6-K | 2024-12-05 | 2024-12-05 | ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED |
| 6-K | 2024-12-02 | 2024-12-02 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-12-02 | 2024-12-02 | TOTAL VOTING RIGHTS |
| 6-K | 2024-11-27 | 2024-11-27 | GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU |
| 6-K | 2024-11-25 | 2024-11-25 | BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW |
| 6-K | 2024-11-22 | 2024-11-22 | JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 |
| 6-K | 2024-11-19 | 2024-11-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-11-19 | 2024-11-19 | GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT |
| 6-K | 2024-11-14 | 2024-11-14 | GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP |
| 6-K | 2024-11-13 | 2024-11-13 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2024-11-12 | 2024-11-12 | GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES |
| 6-K | 2024-11-12 | 2024-11-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-11-01 | 2024-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-10-30 | 2024-10-30 | 3RD QUARTER RESULTS |
| 6-K | 2024-10-30 | 2024-10-30 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-10-24 | 2024-10-24 | NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK |
| 6-K | 2024-10-17 | 2024-10-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-10-16 | 2024-10-16 | FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN |
| 6-K | 2024-10-16 | 2024-10-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-10-15 | 2024-10-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-10-15 | 2024-10-15 | POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB |
| 6-K | 2024-10-11 | 2024-10-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-10-10 | 2024-10-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-10-09 | 2024-10-09 | ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS |
| 6-K | 2024-10-08 | 2024-10-08 | POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS |
| 6-K | 2024-10-01 | 2024-10-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-09-24 | 2024-09-24 | POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE |
| 6-K | 2024-09-24 | 2024-09-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-09-18 | 2024-09-18 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-09-17 | 2024-09-17 | JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA |
| 6-K | 2024-09-13 | 2024-09-13 | CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP |
| 6-K | 2024-09-12 | 2024-09-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-09-12 | 2024-09-12 | POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA |
| 6-K | 2024-09-11 | 2024-09-11 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-09-11 | 2024-09-11 | CHANGE OF REGISTERED OFFICE |
| 6-K | 2024-09-11 | 2024-09-11 | UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL |
| 6-K | 2024-09-09 | 2024-09-09 | DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS |
| 6-K | 2024-09-06 | 2024-09-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-09-06 | 2024-09-06 | POSITIVE PHASE III RESULTS FOR NUCALA IN COPD |
| 6-K | 2024-09-03 | 2024-09-03 | TOTAL VOTING RIGHTS |
| 6-K | 2024-08-29 | 2024-08-29 | EMA APPROVAL ON AREXVY FOR 50-59 AT RISK |
| 6-K | 2024-08-28 | 2024-08-28 | NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP |
| 6-K | 2024-08-28 | 2024-08-28 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-08-28 | 2024-08-28 | SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN |
| 6-K | 2024-08-21 | 2024-08-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-08-20 | 2024-08-20 | B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION |
| 6-K | 2024-08-20 | 2024-08-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-08-16 | 2024-08-16 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-08-12 | 2024-08-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-08-06 | 2024-08-06 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-08-02 | 2024-08-02 | FDA EXPANDS JEMPERLI APPROVAL |
| 6-K | 2024-08-01 | 2024-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-07-31 | 2024-07-31 | 2ND QUARTER RESULTS |
| 6-K | 2024-07-29 | 2024-07-29 | CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK |
| 6-K | 2024-07-29 | 2024-07-29 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-07-19 | 2024-07-19 | BLENREP EMA FILING ACCEPTANCE |
| 6-K | 2024-07-18 | 2024-07-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-07-16 | 2024-07-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-07-15 | 2024-07-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-07-12 | 2024-07-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-07-03 | 2024-07-03 | GSK AND CUREVAC COLLABORATION RESTRUCTURED |
| 6-K | 2024-07-01 | 2024-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-06-28 | 2024-06-28 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-06-24 | 2024-06-24 | EMA VALIDATES JEMPERLI MARKETING AUTHORISATION |
| 6-K | 2024-06-24 | 2024-06-24 | OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS |
| 6-K | 2024-06-21 | 2024-06-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-06-12 | 2024-06-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-06-11 | 2024-06-11 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-06-10 | 2024-06-10 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-06-10 | 2024-06-10 | FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK |
| 6-K | 2024-06-03 | 2024-06-03 | TOTAL VOTING RIGHTS |
| 6-K | 2024-06-03 | 2024-06-03 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-06-03 | 2024-06-03 | ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS |
| 6-K | 2024-06-03 | 2024-06-03 | UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE |
| 6-K | 2024-05-24 | 2024-05-24 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-05-21 | 2024-05-21 | POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB |
| 6-K | 2024-05-20 | 2024-05-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-05-17 | 2024-05-17 | GSK COMPLETES SALE OF SHARES IN HALEON PLC |
| 6-K | 2024-05-17 | 2024-05-17 | CURRENT REPORT |
| 6-K | 2024-05-14 | 2024-05-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-05-13 | 2024-05-13 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2024-05-08 | 2024-05-08 | BOARD COMMITTEE CHANGE |
| 6-K | 2024-05-08 | 2024-05-08 | RESULT OF AGM |
| 6-K | 2024-05-03 | 2024-05-03 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-05-01 | 2024-05-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-05-01 | 2024-05-01 | 1ST QUARTER RESULTS |
| 6-K | 2024-04-24 | 2024-04-24 | US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI |
| 6-K | 2024-04-19 | 2024-04-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-04-17 | 2024-04-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-04-17 | 2024-04-17 | RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX |
| 6-K | 2024-04-17 | 2024-04-17 | GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS |
| 6-K | 2024-04-16 | 2024-04-16 | AMENDMENT - DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-04-16 | 2024-04-16 | FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE |
| 6-K | 2024-04-15 | 2024-04-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-04-02 | 2024-04-02 | TOTAL VOTING RIGHTS |
| 6-K | 2024-03-26 | 2024-03-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-03-25 | 2024-03-25 | NOTICE OF AGM |
| 6-K | 2024-03-22 | 2024-03-22 | TRANSFER OF TREASURY SHARES |
| 6-K | 2024-03-22 | 2024-03-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-03-18 | 2024-03-18 | NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER |
| 6-K | 2024-03-13 | 2024-03-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-03-08 | 2024-03-08 | BOARD COMMITTEE CHANGE |
| 6-K | 2024-03-07 | 2024-03-07 | GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS |
| 6-K | 2024-03-06 | 2024-03-06 | VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED |
| 6-K | 2024-03-05 | 2024-03-05 | GSK ANNUAL REPORT 2023 ON FORM 20 F |
| 20-F | 2023-12-31 | 2024-03-05 | 20-F |
| 6-K | 2024-03-05 | 2024-03-05 | NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING |
| 6-K | 2024-03-01 | 2024-03-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-03-01 | 2024-03-01 | GSK PUBLISHES ANNUAL REPORT 2023 |
| 6-K | 2024-02-29 | 2024-02-29 | DIRECTORATE CHANGE |
| 6-K | 2024-02-29 | 2024-02-29 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-02-26 | 2024-02-26 | GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS |
| 6-K | 2024-02-26 | 2024-02-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-22 | 2024-02-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-21 | 2024-02-21 | VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED |
| 6-K | 2024-02-20 | 2024-02-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-15 | 2024-02-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-15 | 2024-02-15 | GSK COMPLETES ACQUISITION OF AIOLOS BIO |
| 6-K | 2024-02-13 | 2024-02-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-13 | 2024-02-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-13 | 2024-02-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-12 | 2024-02-12 | US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN |
| 6-K | 2024-02-12 | 2024-02-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-12 | 2024-02-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-12 | 2024-02-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-06 | 2024-02-06 | GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA |
| 6-K | 2024-02-06 | 2024-02-06 | FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
| 6-K | 2024-02-06 | 2024-02-06 | SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED |
| 6-K | 2024-02-01 | 2024-02-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-02-01 | 2024-02-01 | TOTAL VOTING RIGHTS |
| 6-K | 2024-02-01 | 2024-02-01 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2024-01-31 | 2024-01-31 | FINAL RESULTS |
| 6-K | 2024-01-29 | 2024-01-29 | EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU |
| 6-K | 2024-01-29 | 2024-01-29 | EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
| 6-K | 2024-01-19 | 2024-01-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-01-16 | 2024-01-17 | CURRENT REPORT |
| 6-K | 2024-01-17 | 2024-01-17 | GSK COMPLETES SALE OF SHARES IN HALEON PLC |
| 6-K | 2024-01-17 | 2024-01-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-01-16 | 2024-01-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2024-01-10 | 2024-01-10 | NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA |
| 6-K | 2024-01-09 | 2024-01-09 | GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO |
| 6-K | 2024-01-02 | 2024-01-02 | TOTAL VOTING RIGHTS |
| 6-K | 2023-12-21 | 2023-12-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-12-18 | 2023-12-18 | JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT |
| 6-K | 2023-12-13 | 2023-12-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-12-11 | 2023-12-12 | JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS |
| 6-K | 2023-12-11 | 2023-12-11 | JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION |
| 6-K | 2023-12-04 | 2023-12-04 | GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES |
| 6-K | 2023-12-01 | 2023-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-11-30 | 2023-11-30 | BLOCK LISTING APPLICATION |
| 6-K | 2023-11-29 | 2023-11-29 | HOLDING(S) IN COMPANY |
| 6-K | 2023-11-27 | 2023-11-27 | GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS |
| 6-K | 2023-11-21 | 2023-11-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-11-15 | 2023-11-15 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2023-11-13 | 2023-11-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-11-13 | 2023-11-13 | GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB |
| 6-K | 2023-11-01 | 2023-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-11-01 | 2023-11-01 | 3RD QUARTER RESULTS |
| 6-K | 2023-10-30 | 2023-10-30 | JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT |
| 6-K | 2023-10-26 | 2023-10-26 | NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA |
| 6-K | 2023-10-25 | 2023-10-25 | NEW DATA FOR AREXVY, GSK'S RSV VACCINE |
| 6-K | 2023-10-25 | 2023-10-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-10-20 | 2023-10-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-10-18 | 2023-10-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-10-17 | 2023-10-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-10-16 | 2023-10-16 | JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION |
| 6-K | 2023-10-13 | 2023-10-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-10-12 | 2023-10-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-10-11 | 2023-10-11 | ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2023-10-10 | 2023-10-10 | GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP |
| 6-K | 2023-10-06 | 2023-10-06 | CURRENT REPORT |
| 6-K | 2023-10-06 | 2023-10-06 | GSK COMPLETES SALE OF SHARES IN HALEON PLC |
| 6-K | 2023-10-02 | 2023-10-02 | TOTAL VOTING RIGHTS |
| 6-K | 2023-09-27 | 2023-09-27 | DIRECTORATE CHANGE |
| 6-K | 2023-09-25 | 2023-09-25 | GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN |
| 6-K | 2023-08-21 | 2023-09-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-09-19 | 2023-09-19 | APRETUDE FOR PREP RECEIVES EMA APPROVAL |
| 6-K | 2023-09-18 | 2023-09-18 | FDA APPROVES OJJAARA (MOMELOTINIB) |
| 6-K | 2023-09-13 | 2023-09-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-09-11 | 2023-09-11 | MOMELOTINIB FILING ACCEPTED IN JAPAN |
| 6-K | 2023-09-11 | 2023-09-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-09-06 | 2023-09-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-09-01 | 2023-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-09-01 | 2023-09-01 | GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN |
| 6-K | 2023-08-31 | 2023-08-31 | HOLDING(S) IN COMPANY |
| 6-K | 2023-08-31 | 2023-08-31 | HOLDING(S) IN COMPANY |
| 6-K | 2023-08-25 | 2023-08-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-08-23 | 2023-08-23 | SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINA |
| 6-K | 2023-08-23 | 2023-08-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-08-22 | 2023-08-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-08-10 | 2023-08-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-08-09 | 2023-08-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-08-01 | 2023-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-07-31 | 2023-07-31 | FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMO |
| 6-K | 2023-07-31 | 2023-07-31 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-07-28 | 2023-07-28 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-07-26 | 2023-07-26 | 2ND QUARTER RESULTS |
| 6-K | 2023-07-24 | 2023-07-24 | CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP |
| 6-K | 2023-07-20 | 2023-07-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-07-17 | 2023-07-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-07-13 | 2023-07-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-07-03 | 2023-07-03 | TOTAL VOTING RIGHTS |
| 6-K | 2023-06-28 | 2023-06-28 | GSK COMPLETES ACQUISITION OF BELLUS HEALTH |
| 6-K | 2023-06-27 | 2023-06-27 | FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE |
| 6-K | 2023-06-26 | 2023-06-26 | GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION |
| 6-K | 2023-06-26 | 2023-06-26 | SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER |
| 6-K | 2023-06-23 | 2023-06-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-06-23 | 2023-06-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-06-23 | 2023-06-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-06-23 | 2023-06-23 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2023-06-22 | 2023-06-22 | GSKS AREXVY RECOMMENDED BY ACIP |
| 6-K | 2023-06-21 | 2023-06-21 | SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE |
| 6-K | 2023-06-16 | 2023-06-16 | EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB |
| 6-K | 2023-06-12 | 2023-06-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-06-07 | 2023-06-07 | EU AUTHORISATION OF GSKS RSV VACCINE AREXVY |
| 6-K | 2023-06-06 | 2023-06-06 | GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI |
| 6-K | 2023-06-01 | 2023-06-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-05-22 | 2023-05-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-05-15 | 2023-05-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-05-15 | 2023-05-15 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2023-05-12 | 2023-05-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-05-11 | 2023-05-12 | CURRENT REPORT OF FOREIGN ISSUER |
| 6-K | 2023-05-12 | 2023-05-12 | GSK COMPLETES SALE OF SHARES IN HALEON PLC |
| 6-K | 2023-05-12 | 2023-05-12 | STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA |
| 6-K | 2023-05-12 | 2023-05-12 | MENABCWY VACCINE PRELIMINARY PHASE III RESULTS |
| 6-K | 2023-05-09 | 2023-05-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-05-04 | 2023-05-04 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-05-03 | 2023-05-03 | RESULT OF AGM |
| 6-K | 2023-05-03 | 2023-05-03 | US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS |
| 6-K | 2023-05-02 | 2023-05-02 | TOTAL VOTING RIGHTS |
| 6-K | 2023-04-28 | 2023-04-28 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-04-27 | 2023-04-27 | GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION |
| 6-K | 2023-04-26 | 2023-04-26 | 1ST QUARTER RESULTS |
| 6-K | 2023-04-25 | 2023-04-25 | EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION |
| 6-K | 2023-04-20 | 2023-04-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-04-19 | 2023-04-19 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-04-18 | 2023-04-18 | GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC |
| 6-K | 2023-04-17 | 2023-04-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-04-17 | 2023-04-17 | GEPOTIDACIN POSITIVE PHASE III DATA |
| 6-K | 2023-04-03 | 2023-04-03 | TOTAL VOTING RIGHTS |
| 6-K | 2023-03-28 | 2023-03-28 | POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI |
| 6-K | 2023-03-27 | 2023-03-27 | PUBLICATION OF 2023 AGM NOTICE |
| 6-K | 2023-03-24 | 2023-03-24 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2023-03-21 | 2023-03-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-03-20 | 2023-03-20 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-03-14 | 2023-03-14 | POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE |
| 6-K | 2023-03-14 | 2023-03-14 | NUCALA NDA ACCEPTED FOR REVIEW IN CHINA |
| 6-K | 2023-03-13 | 2023-03-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-03-10 | 2023-03-10 | GSK ANNUAL REPORT 2022 ON FORM 20-F |
| 20-F | 2022-12-31 | 2023-03-10 | 20-F |
| 6-K | 2023-03-10 | 2023-03-10 | GSK PUBLISHES ANNUAL REPORT 2022 |
| 6-K | 2023-03-02 | 2023-03-02 | FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE |
| 6-K | 2023-03-01 | 2023-03-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-02-27 | 2023-02-27 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-23 | 2023-02-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-23 | 2023-02-23 | VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA |
| 6-K | 2023-02-22 | 2023-02-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-16 | 2023-02-16 | NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL |
| 6-K | 2023-02-15 | 2023-02-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-15 | 2023-02-15 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-14 | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-14 | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-14 | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-14 | 2023-02-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-10 | 2023-02-10 | JEMPERLI FDA ODAC POSITIVE OUTCOME |
| 6-K | 2023-02-10 | 2023-02-10 | JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL |
| 6-K | 2023-02-10 | 2023-02-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-02 | 2023-02-02 | DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD |
| 6-K | 2023-02-01 | 2023-02-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-02-01 | 2023-02-01 | FINAL RESULTS |
| 6-K | 2023-02-01 | 2023-02-01 | BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA |
| 6-K | 2023-02-01 | 2023-02-01 | TOTAL VOTING RIGHTS |
| 6-K | 2023-01-18 | 2023-01-18 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-01-17 | 2023-01-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-01-17 | 2023-01-17 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-01-13 | 2023-01-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-01-12 | 2023-01-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2023-01-03 | 2023-01-03 | TOTAL VOTING RIGHTS |
| 6-K | 2022-12-22 | 2022-12-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-12-21 | 2022-12-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-12-21 | 2022-12-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-12-15 | 2022-12-15 | BOARD AND COMMITTEE CHANGES |
| 6-K | 2022-12-13 | 2022-12-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-12-07 | 2022-12-07 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2022-12-05 | 2022-12-05 | TRANSFER OF TREASURY SHARES |
| 6-K | 2022-12-02 | 2022-12-02 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-12-02 | 2022-12-02 | JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER |
| 6-K | 2022-12-02 | 2022-12-02 | EMA FILE ACCEPTED FOR MOMELOTINIB |
| 6-K | 2022-12-01 | 2022-12-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-11-25 | 2022-11-25 | GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES |
| 6-K | 2022-11-22 | 2022-11-22 | BLENREP US UPDATE |
| 6-K | 2022-11-21 | 2022-11-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-11-15 | 2022-11-15 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2022-11-14 | 2022-11-14 | GSK UPDATE: ZEJULA 2L IN US |
| 6-K | 2022-11-10 | 2022-11-10 | BLOCK LISTING APPLICATION |
| 6-K | 2022-11-10 | 2022-11-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-11-10 | 2022-11-10 | SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU |
| 6-K | 2022-11-07 | 2022-11-07 | DREAMM-3 PHASE III TRIAL FOR BLENREP |
| 6-K | 2022-11-03 | 2022-11-03 | IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP |
| 6-K | 2022-11-02 | 2022-11-02 | GSK RSV VACCINE: US FDA PRIORITY REVIEW |
| 6-K | 2022-11-02 | 2022-11-02 | 3RD QUARTER RESULTS |
| 6-K | 2022-11-01 | 2022-11-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-10-28 | 2022-10-28 | EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP |
| 6-K | 2022-10-28 | 2022-10-28 | EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW |
| 6-K | 2022-10-27 | 2022-10-27 | CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE |
| 6-K | 2022-10-27 | 2022-10-27 | GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT |
| 6-K | 2022-10-25 | 2022-10-25 | BOARD COMMITTEE CHANGES |
| 6-K | 2022-10-21 | 2022-10-21 | RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN |
| 6-K | 2022-10-17 | 2022-10-17 | MENVEO NEW SINGLE-VIAL APPROVED BY US FDA |
| 6-K | 2022-10-14 | 2022-10-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-10-13 | 2022-10-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-10-13 | 2022-10-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-10-13 | 2022-10-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-10-13 | 2022-10-13 | EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE |
| 6-K | 2022-10-12 | 2022-10-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-10-11 | 2022-10-11 | US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION |
| 6-K | 2022-10-07 | 2022-10-07 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-10-07 | 2022-10-07 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-10-03 | 2022-10-03 | TOTAL VOTING RIGHTS |
| 6-K | 2022-09-30 | 2022-09-30 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-09-26 | 2022-09-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-09-26 | 2022-09-26 | GSK CHIEF FINANCIAL OFFICER SUCCESSION |
| 6-K | 2022-09-22 | 2022-09-22 | GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM |
| 6-K | 2022-09-22 | 2022-09-22 | US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL |
| 6-K | 2022-09-21 | 2022-09-21 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-09-13 | 2022-09-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-09-08 | 2022-09-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-09-06 | 2022-09-06 | GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT |
| 6-K | 2022-09-01 | 2022-09-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-08-24 | 2022-08-24 | GSK BOARD CHANGES |
| 6-K | 2022-08-22 | 2022-08-22 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-08-17 | 2022-08-17 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE |
| 6-K | 2022-08-17 | 2022-08-17 | FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB |
| 6-K | 2022-08-16 | 2022-08-16 | GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. |
| 6-K | 2022-08-12 | 2022-08-12 | STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
| 6-K | 2022-08-11 | 2022-08-11 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-08-10 | 2022-08-10 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-08-03 | 2022-08-03 | CURRENT REPORT OF FOREIGN ISSUER |
| 6-K | 2022-08-01 | 2022-08-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-08-01 | 2022-08-01 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-29 | 2022-07-29 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-29 | 2022-07-29 | GSK BOARD CHANGE |
| 6-K | 2022-07-28 | 2022-07-28 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-27 | 2022-07-27 | 2ND QUARTER RESULTS |
| 6-K | 2022-07-22 | 2022-07-22 | HOLDING(S) IN COMPANY |
| 6-K | 2022-07-22 | 2022-07-22 | BOARD AND COMMITTEE CHANGES |
| 6-K | 2022-07-18 | 2022-07-18 | COMPLETION OF GSK SHARE CONSOLIDATION |
| 6-K | 2022-07-18 | 2022-07-18 | HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATION |
| 6-K | 2022-07-12 | 2022-07-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-08 | 2022-07-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-08 | 2022-07-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-08 | 2022-07-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-08 | 2022-07-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-08 | 2022-07-08 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-06 | 2022-07-06 | RESULT OF GENERAL MEETING |
| 6-K | 2022-07-06 | 2022-07-06 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-05 | 2022-07-05 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-05 | 2022-07-05 | GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022 |
| 6-K | 2022-07-05 | 2022-07-05 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-07-01 | 2022-07-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-07-01 | 2022-07-01 | GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGY |
| 6-K | 2022-06-28 | 2022-06-28 | GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN |
| 6-K | 2022-06-28 | 2022-06-28 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-06-27 | 2022-06-27 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-06-24 | 2022-06-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-06-16 | 2022-06-16 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-06-10 | 2022-06-10 | POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE |
| 6-K | 2022-06-09 | 2022-06-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-06-07 | 2022-06-07 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-06-06 | 2022-06-06 | US FDA APPROVAL OF PRIORIX |
| 6-K | 2022-06-01 | 2022-06-01 | DEMERGER UPDATE: PUBLICATION OF DOCUMENTS |
| 6-K | 2022-06-01 | 2022-06-01 | 6-K |
| 6-K | 2022-06-01 | 2022-06-01 | DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCA |
| 6-K | 2022-05-31 | 2022-05-31 | GSK TO ACQUIRE AFFINIVAX, INC. |
| 6-K | 2022-05-31 | 2022-05-31 | FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD |
| 6-K | 2022-05-26 | 2022-05-27 | GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA |
| 6-K | 2022-05-25 | 2022-05-25 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-05-23 | 2022-05-23 | FORM 6-K |
| 6-K | 2022-05-19 | 2022-05-19 | IAIN MACKAY - EXTERNAL APPOINTMENT |
| 6-K | 2022-05-16 | 2022-05-16 | CHANGE OF NAME TO GSK PLC |
| 6-K | 2022-05-13 | 2022-05-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-05-12 | 2022-05-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-05-11 | 2022-05-11 | BLOCK LISTING INTERIM REVIEW |
| 6-K | 2022-05-09 | 2022-05-09 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-05-04 | 2022-05-04 | DIRECTORATE CHANGE |
| 6-K | 2022-05-04 | 2022-05-04 | RESULT OF AGM |
| 6-K | 2022-05-03 | 2022-05-03 | TOTAL VOTING RIGHTS |
| 6-K | 2022-04-27 | 2022-04-27 | 1ST QUARTER RESULTS |
| 6-K | 2022-04-26 | 2022-04-26 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-19 | 2022-04-19 | DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA |
| 6-K | 2022-04-14 | 2022-04-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-14 | 2022-04-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-14 | 2022-04-14 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-13 | 2022-04-13 | GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN |
| 6-K | 2022-04-13 | 2022-04-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-13 | 2022-04-13 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-12 | 2022-04-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-12 | 2022-04-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-12 | 2022-04-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-12 | 2022-04-12 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-04-01 | 2022-04-01 | TOTAL VOTING RIGHTS |
| 6-K | 2022-04-01 | 2022-04-01 | GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES |
| 6-K | 2022-03-28 | 2022-03-28 | PUBLICATION OF 2022 AGM NOTICE |
| 6-K | 2022-03-24 | 2022-03-24 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-03-24 | 2022-03-24 | FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL |
| 6-K | 2022-03-23 | 2022-03-23 | DIRECTOR/PDMR SHAREHOLDING |
| 6-K | 2022-03-23 | 2022-03-23 | ISSUANCE OF NOTES |